The Zhitong Finance App learned that CMB International released a research report saying that it gave Ricoh Bio-B (02179) a “buy” rating, but due to the current decline in demand for the COVID-19 vaccine and the intensification of domestic COVID-19 vaccine competition, expectations for its COVID-19 vaccine ReCoV were lowered from HK$38.86 to HK$20.96. The company's COVID-19 vaccine, ReCoV, obtained emergency use authorization in Mongolia in March 2023, and has submitted product marketing applications to the Chinese regulatory authorities on a rolling basis. It is expected to be approved this year and contribute to sales revenue next year.

According to the report, in terms of other pipelines,9-valent HPV vaccine, REC603:A total of 1,6050 subjects were enrolled in the phase III clinical trial, and clinical follow-up is ongoing. Currently, there are 5 domestic 9-valent HPV vaccines in clinical phase III. The bank expects the company to submit a BLA application in 2025 and become the first batch of domestically produced 9-valent HPV vaccines to be approved.Herpes zoster vaccine, REC610:A head-to-head clinical phase I trial with GSK's Shingrix is currently underway in the Philippines. Clinical data is expected to be obtained in the second half of this year. Furthermore, the company plans to launch phase I clinical trials in China within the year and start phase III clinical trials in China in 2024. Currently, there are 3 domestic recombinant shingles vaccines in the clinical stage. The bank expects the company to submit BLA applications in 2025.